Aktis Oncology, Inc. Common stock
AKTSStock
$25.02−82.46%52W
Market Cap$1.44B
P/E—
Div yield—
Beta155.43
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-80.97%
Price vs S&P 500 (4W)14.29%
VGM Score56.76
Market Capitalization$1.44B
Earnings Surprise History
Q1 26-0.38est. -0.34
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.27
4.33
4.33
4.38
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AKTSAktis Oncology, Inc. Common stock | — | B | D | $25.02 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Aktis Oncology is a clinical-stage oncology company developing targeted alpha radiopharmaceuticals for solid tumors, including breast, lung, colorectal, bladder, and liver cancers. The company focuses on expanding access to large patient populations not addressed by existing platform technologies. Its pipeline includes AKY-1189 and AKY-2519.